Abstract
Until the middle of the last century, achievement of abstinence was the only available treatment option for opioid dependence. Most often, addicts were simply expected to go “cold turkey,” although abstinence was sometimes accomplished by way of inpatient hospitalization with adjunctive medications to help alleviate symptoms of craving and withdrawal. The general belief, however, was that abstinence was best achieved by correcting the addict’s underlying psychopathology, which would result in the addiction simply going away. Rarely were addicts able to remain off drugs long enough to be truly rehabilitated, however, and for the most part, even after long hospitalizations, relapse was the predictable outcome.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Dole, V. and Nyswander, M. (1965) A medical treatment for diacetylmorphine (heroin) addiction. JAMA 193, 646–650.
Sees, K. L., Delucchi, K. L., Carmen, M., Rosen, A., Clark, H. W., Robillard, H., et al. (2000) Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence. JAMA 283(10), 1303–1310.
Wolff, K., Hay, A. W. M., Raistrick, D., and Calvert, R. (1993) Steady-state pharmacokinetics of methadone in opioid addicts. Eur. J. Clin. Pharmacol. 44, 189–194.
Nilsson, M. J., Widelov, E., Meresaar, U., and Anggard, E. (1982) Effect of urinary ph on the disposition of methadone in man. Eur. J. Clin. Pharmacol. 22, 337–342.
Garrido, J. M. and Troconiz, I. F. (1999) Methadone: a review of its pharmacokinetic/pharmacodynamic properties. J. Pharmacol. Toxicol. 42, 61–66.
Chen, K. K (1948) Pharmacology of methadone and related compounds. Ann. NY Acad. Sci. 51, 83–87.
Fraser, H. F. and Isbell, H. (1952) Actions and addiction liabilities of alpha-acetylmethadols in man. J. Pharmacol. Exper. Ther. 105, 458–465.
Misra, A. L. and Mule, S. J. (1975) L-a-Acetylmethadol (LAAM) pharmacokinetics and metabolism: current status. Am. J. Drug Alcohol Abuse 2, 301–305.
Research Triangle Institute (1984, Sept.) Bioavailability and pharmacokinetics/pharmacodynamics of L-a-acetylmethadol and its metabolites: metabolism and pharmacokinetics of drugs. Final Rep. Contr. #771-80-3705, Task #2.
Toro-Goyco, E., Martin, B. R., and Harris, L. S. (1980) The binding of LAAM and its metabolites to blood constituents, in Problems of Drug Dependence. 1979: Proc. 41st Ann. Sci. Mtg. Comm. Problems of Drug Dependence. NIDA Research Monograph #27 (Harris, L.S., ed.), Wash. DC, pp. 54–60.
Misra, A. L., Mule, S. J., Bloch, R., and Bates, T. R. (1978) Physiological disposition and biotransformation of l-a-[2-H] acetylmethadol (LAAM) in acutely and chronically treated monkeys. J. Pharmacol. Exper. Ther. 206(2), 475–491.
Jasinski, D. R., Pevnick, J. S., and Griffith, J. D. (1978) Human pharmacology and abuse potential of the analgesic buprenorphine. Arch. Gen. Psych. 35, 501–516.
Lewis, J. W. (1985) Buprenorphine. Drug Alcohol Dep. 14, 363–372.
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., and Bigelow, G.,E. (1994) Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther. 55(5), 569–580.
Walter, D. S. and Inturrisi, C. E. (1995) Absorption, distribution, metabolism and excretion of buprenorphine in animals and humans in Buprenorphine: combining drug abuse with a unique opioid, (Wiley-Liss, ed.), pp. 113–135.
Archer, S. (1980) Historical perspective on the chemistry and development of naltrexone, in National Institute on Drug Abuse Monograph Series 28: Narcotic Antagonists: Naltrexone Pharmacochemistry and Sustained-Release Preparations (Willette, R.,E. and Barnett, G. eds.), National Institute on Drug Abuse Monograph Series. Rockville, MD, pp. 3–10.
Martin, W. R., Jasinski, D. R. and Mansley, P. A. (1973) Naltrexone, an antagonist for the treatment of heroin dependence. Arch. Gen. Psych. 28, 784–791.
Crowley, T. J., Wagner, J. E., Zerbe, G., and Mcdonald, M. (1985) Naltrexone-induced dysphoria in former opiate addicts. Am. J. Psych. 142, 1081–1084.
Rawson, R. A. and Ling, W (1991) Opioid addiction treatment. J. Psychoact. Drugs 23(2), 151–163.
Hall, S. M. (1983) Methadone treatment: a review of research findings, in National Institute on Drug Abuse Series: Research on the Treatment of Narcotic Addiction: State of the Art (Cooper, J. R., Altman, F., Brown, B. S., and Czechowicz, D. eds.), National Institute on Drug Abuse Treatment Monograph Series. Rockville, MD.
U.S. Congress. H.R.4365 “The Children’s Health Act of 2000.” (Signed Oct. 17, 2000) Section 3502 “Drug Addiction Treatment Act of 2000.”
Kintz, P. (2001) Deaths involving buprenorphine: a compendium of French cases. Forensic Sci. Int. 121, 65–69.
Ling, W. and Compton, P. (1997) Opiate maintenance therapy with LAAM, in New Treatments for Opiate Dependence (Stine, S. M. and Kosten, T. R., eds.), Guilford, New York, pp. 231–253.
Wesson, D. R. and Ling, W. (1991) Medications in the treatment of addictive disease. J. Psychoact. Drugs 23(4), 365–370.
Ling, W., Huber, A., and Rawson, R. A. (2001) New trends in opiate pharmacotherapy. Drug Alcohol Rev. 20, 79–94.
Gold, M. S., Pottash, A. L., Sweeney, D. R., and Kleber, H. D. (1980) Efficacy of clonidine in opiate withdrawal: a study of thirty patients. Drug Alcohol Abuse 6, 201–208.
Kleber, H. D., Topazian, M., Gaspari, J., Riordan, C. E., and Kosten, T. (1987) Clonidine and naltrexone in the outpatients treatment of heroin withdrawal. Am. J. Drug Alcohol Abuse 13, 1–17.
Dole, V. P. and Nyswander, M. E (1983) Pharmacological treatment of narcotic addiction (the eighth Nathan B. Eddy memorial award lecture) in NIDA Research Monograph #43. National Institute on Drug Abuse Treatment Monograph Series. Rockville, MD, pp. 5–9.
Jasinski, D. R., Pevnick, J. S., and Griffith, J. D. (1978) Human pharmacology and abuse potential of the analgesic buprenorphine. Arch. Gen. Psych. 35, 501–516.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc.
About this protocol
Cite this protocol
Ling, W., Rawson, R.A., Compton, M. (2003). Clinical Treatment of Opioid Addiction and Dependence. In: Pan, Z.Z. (eds) Opioid Research. Methods in Molecular Biology™, vol 84. Humana Press. https://doi.org/10.1385/1-59259-379-8:285
Download citation
DOI: https://doi.org/10.1385/1-59259-379-8:285
Publisher Name: Humana Press
Print ISBN: 978-1-58829-059-5
Online ISBN: 978-1-59259-379-8
eBook Packages: Springer Protocols